黄芩苷在二乙基亚硝胺诱发肝癌前病变小鼠体内药动学考察  

Pharmacokinetics of baicalin in hepatic precancerous mice induced by diethylnitrosamine

作　　者：冯丽莉[1] 张健[1] 毛文超[1] 王秀萍[1] 张东星[1] 王湘[1] 蔡大勇[2] 王玥琦[1] 

机构地区：[1]北京中医药大学基础医学院,北京100029 [2]中国医学科学院药用植物研究所,北京100093

出　　处：《中华中医药杂志》2013年第10期3063-3067,共5页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：北京中医药大学创新团队项目(No.2011-CXD-04)~~

摘　　要：目的:考察黄芩苷在正常和二乙基亚硝胺诱发肝癌前病变模型小鼠体内的药物动力学差异。方法:分别灌胃给予正常和模型小鼠3个剂量的黄芩苷,采用HPLC测定其在不同时间点的血药浓度,根据药时曲线计算药代动力学参数。结果:正常和模型小鼠药时曲线下面积(AUC)均随给药剂量增加而加大,其中模型组各剂量组之间存在显著差异(P<0.05),平均滞留时间(MRT)无显著差异;当给药剂量相同时,3个剂量的模型组小鼠AUC值明显低于正常组(P<0.05),但MRT、半衰期(t1/2)等参数无显著差异。结论:黄芩苷在模型动物体内的药物动力学与正常状态存在一定差异。Objective： To investigate the pharmacokinetic difference of baicalin between hepatic precancerous model induced by diethylnitrosamine and control mice. Methods： Baicalin was administrated intragastrically to both control and model mice at three different doses, and the concentration of baicalin in plasma at defined time was determined by HPLC to calculate its pharmacokinetic parameters. Results： Values of area under the curve （AUC） in both control and model mice increased with the increasing doses, and significant differences existed among different doses in model mice （P〈0.05）, however, mean residence time （MRT） had no significant difference; when the mice were treated at the same dose, the AUC in model mice were significantly less than that in control ones （P〈0.05）, while other parameters such as MRT and t1/2 had no significant difference. Conclusion： Pharmacokinetics of baicalin in model mice is different from that in control ones.

关 键 词：黄芩苷 肝癌前病变模型 药动学 小鼠 

分 类 号：R285[医药卫生—中药学]